Ignite Creation Date:
2025-12-25 @ 12:33 AM
Ignite Modification Date:
2026-02-20 @ 5:57 PM
Study NCT ID:
NCT02572167
Status:
COMPLETED
Last Update Posted:
2022-11-08
First Post:
2015-10-07
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Sponsor:
Seagen Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-10-31
Start Date Type:
ACTUAL
Primary Completion Date:
2018-03-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-10-21
Completion Date Type:
ACTUAL
First Submit Date:
2015-10-07
First Submit QC Date:
None
Study First Post Date:
2015-10-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-02-13
Results First Submit QC Date:
None
Results First Post Date:
2019-03-07
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-10-17
Last Update Post Date:
2022-11-08
Last Update Post Date Type:
ACTUAL